Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DSGN Design Therapeutics	$5.17 -4.6%	$3.99	$2.60 ▼ $7.77	$294.48M	1.58	133,237 shs	20,464 shs
NTLA Intellia Therapeutics	$10.97 -0.2%	$10.75	$5.90 ▼ $24.16	$1.18B	2.31	4.09 million shs	4.61 million shs
SNDX Syndax Pharmaceuticals	$14.66 +9.0%	$10.20	$8.58 ▼ $22.50	$1.26B	0.74	2.23 million shs	1.64 million shs
TLRY Tilray Brands	$1.18 -6.0%	$0.56	$0.35 ▼ $1.98	$1.29B	1.85	40.18 million shs	137.75 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DSGN Design Therapeutics	+8.84%	+24.60%	+35.50%	+61.31%	+22.90%
NTLA Intellia Therapeutics	+1.29%	-3.25%	-7.95%	+36.31%	-50.91%
SNDX Syndax Pharmaceuticals	+3.70%	+4.34%	+36.55%	+50.28%	-32.31%
TLRY Tilray Brands	+31.51%	+102.53%	+90.32%	+184.09%	-32.98%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DSGN Design Therapeutics	0.1402 of 5 stars	0.0	1.0	0.0	1.0	2.5	0.0
NTLA Intellia Therapeutics	4.6313 of 5 stars	4.3	2.0	4.7	2.9	2.5	0.6
SNDX Syndax Pharmaceuticals	4.1268 of 5 stars	4.5	1.0	4.4	2.6	0.8	0.0
TLRY Tilray Brands	2.9445 of 5 stars	3.1	3.0	0.0	3.1	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DSGN Design Therapeutics	0.00	N/A	N/A	N/A
NTLA Intellia Therapeutics	2.58	Moderate Buy	$29.05	164.76% Upside
SNDX Syndax Pharmaceuticals	3.00	Buy	$36.91	151.70% Upside
TLRY Tilray Brands	2.20	Hold	$1.92	63.12% Upside

Current Analyst Ratings Breakdown

Latest DSGN, NTLA, TLRY, and SNDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	NTLA Intellia Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
8/11/2025	NTLA Intellia Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$68.00 ➝ $60.00
8/8/2025	NTLA Intellia Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$50.00 ➝ $45.00
8/8/2025	NTLA Intellia Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$25.00 ➝ $21.00
8/8/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $25.00
8/6/2025	SNDX Syndax Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/5/2025	SNDX Syndax Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$46.00 ➝ $51.00
8/5/2025	SNDX Syndax Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$43.00 ➝ $56.00
7/29/2025	TLRY Tilray Brands	Zelman & Associates Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
7/15/2025	SNDX Syndax Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$37.00 ➝ $35.00
7/10/2025	SNDX Syndax Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$18.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$3.74 per share	N/A
NTLA Intellia Therapeutics	$57.88M	20.35	N/A	N/A	$6.66 per share	1.65
SNDX Syndax Pharmaceuticals	$23.68M	53.34	N/A	N/A	$1.83 per share	8.01
TLRY Tilray Brands	$821.31M	1.57	$0.18 per share	6.58	$1.40 per share	0.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DSGN Design Therapeutics	-$49.59M	-$1.12	N/A	N/A	N/A	N/A	-27.15%	-26.07%	N/A
NTLA Intellia Therapeutics	-$519.02M	-$4.69	N/A	N/A	N/A	-908.48%	-57.48%	-45.04%	N/A
SNDX Syndax Pharmaceuticals	-$318.76M	-$3.89	N/A	N/A	N/A	-428.48%	-130.47%	-56.12%	N/A
TLRY Tilray Brands	-$2.19B	-$2.31	N/A	N/A	N/A	-265.69%	-6.83%	-5.45%	10/9/2025 (Estimated)

Latest DSGN, NTLA, TLRY, and SNDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q1 2025	DSGN Design Therapeutics	-$0.32	-$0.34	-$0.02	-$0.34	N/A	N/A
8/7/2025	Q2 2025	NTLA Intellia Therapeutics	-$1.03	-$0.99	+$0.04	-$0.98	$12.26 million	$14.25 million
8/4/2025	Q2 2025	SNDX Syndax Pharmaceuticals	-$1.01	-$0.83	+$0.18	-$0.83	$26.64 million	$37.96 million
7/28/2025	Q4 2025	TLRY Tilray Brands	-$0.03	$0.02	+$0.05	-$1.30	$250.41 million	$224.54 million
5/14/2025	Q1 2025	DSGN Design Therapeutics	-$0.28	-$0.31	-$0.03	-$0.31	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TLRY Tilray Brands	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DSGN Design Therapeutics	N/A	25.13	25.13
NTLA Intellia Therapeutics	N/A	5.19	4.90
SNDX Syndax Pharmaceuticals	2.06	4.71	4.55
TLRY Tilray Brands	0.20	2.46	1.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DSGN Design Therapeutics	56.64%
NTLA Intellia Therapeutics	88.77%
SNDX Syndax Pharmaceuticals	N/A
TLRY Tilray Brands	9.35%

Insider Ownership

Company	Insider Ownership
DSGN Design Therapeutics	23.50%
NTLA Intellia Therapeutics	3.10%
SNDX Syndax Pharmaceuticals	4.10%
TLRY Tilray Brands	0.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DSGN Design Therapeutics	40	56.95 million	43.57 million	Optionable
NTLA Intellia Therapeutics	600	107.35 million	104.02 million	Optionable
SNDX Syndax Pharmaceuticals	110	86.14 million	82.61 million	Optionable
TLRY Tilray Brands	2,842	1.10 billion	1.09 billion	Optionable

DSGN, NTLA, TLRY, and SNDX Headlines

Recent News About These Companies

Tilray Brands: Improving Fundamentals, De-Risked Balance Sheet, And A Re-Igniting Narrative

3 hours ago | seekingalpha.com

Tilray Brands (NASDAQ:TLRY) Shares Gap Down - Time to Sell?

4 hours ago | marketbeat.com

Tilray Brands Reconfirms Strategy to Regain Nasdaq Compliance; Requests Extension to Meet Listing Requirements

August 14 at 7:00 AM | globenewswire.com

Tilray Brands (NASDAQ:TLRY) Shares Up 17.3% - Here's Why

August 13 at 4:19 PM | marketbeat.com

Promising Cannabis Stocks To Add to Your Watchlist - August 13th

August 13 at 1:15 PM | marketbeat.com

Why Tilray Should Be Reduced

August 13 at 9:14 AM | seekingalpha.com

TLRY Q2 Deep Dive: Regulatory Delays, Margin Focus, and International Momentum Shape Results

August 13 at 9:14 AM | finance.yahoo.com

Tilray Medical Forms Strategic Partnership in Italy to Broaden Access to Medical Cannabis Extracts

August 13 at 7:00 AM | globenewswire.com

Tilray Brands (NASDAQ:TLRY) Stock Price Up 9.2% - Here's What Happened

August 12 at 3:01 PM | marketbeat.com

Promising Cannabis Stocks To Keep An Eye On - August 12th

August 12 at 2:29 PM | marketbeat.com

Tilray Brands (NASDAQ:TLRY) Sees Unusually-High Trading Volume - Should You Buy?

August 12 at 1:09 PM | marketbeat.com

Is Tilray stock price rally a trap? history suggests selling

August 12 at 12:11 PM | invezz.comI

Tilray Expands Hemp-Derived Delta-9 THC Beverage Lineup with 10mg Drinks from Fizzy Jane’s and Happy Flower Brands

August 12 at 7:07 AM | financialpost.comF

Tilray Brands: Is TLRY Stock The Next Big Thing?

August 12 at 7:01 AM | forbes.com

Tilray Expands Hemp-Derived Delta-9 THC Beverage Lineup with 10mg Drinks from Fizzy Jane's and Happy Flower Brands

August 12 at 7:00 AM | globenewswire.com

Traders Buy High Volume of Call Options on Tilray Brands (NASDAQ:TLRY)

August 12 at 2:13 AM | americanbankingnews.com

Tilray Brands (NASDAQ:TLRY) Trading Up 14.4% - Time to Buy?

August 11 at 4:34 PM | marketbeat.com

Cannabis stocks surge as Trump consider reclassifying the drug

August 11 at 3:18 PM | proactiveinvestors.com

Tilray Brands (NASDAQ:TLRY) Shares Gap Up - Should You Buy?

August 11 at 1:54 PM | marketbeat.com

Tilray Brands Sees Unusually Large Options Volume (NASDAQ:TLRY)

August 11 at 11:32 AM | marketbeat.com

Cannabis stocks rally on Wall Street Journal report that Trump is weighing drug reclassification

August 11 at 10:50 AM | cnbc.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

DSGN, NTLA, TLRY, and SNDX Company Descriptions

Design Therapeutics NASDAQ:DSGN

$5.17 -0.25 (-4.61%)

As of 03:03 PM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Intellia Therapeutics NASDAQ:NTLA

$10.97 -0.03 (-0.25%)

As of 03:04 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Syndax Pharmaceuticals NASDAQ:SNDX

$14.66 +1.21 (+9.03%)

As of 03:04 PM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Tilray Brands NASDAQ:TLRY

$1.18 -0.08 (-6.00%)

As of 03:04 PM Eastern

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time